Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth,
NJ 07033-0530
United States - Map
Phone: 908-298-4000
Fax: 908-298-7082
Web Site: http://www.schering-plough.com
| Schering-Plough Corporation discovers, develops, manufactures, and sells pharmaceuticals worldwide. It operates in three segments: Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. The Prescription Pharmaceuticals segment offers human pharmaceutical products in six therapeutic areas, including cardiovascular, central nervous system, immunology and infectious disease, oncology, respiratory, and womens health. This segment sells its products through wholesale and specialty distributors, hospitals, managed care organizations, retail and specialty pharmacists, and government agencies. The Animal Health segment discovers, develops, manufactures, and markets animal health products, including vaccines. Its products include livestock products, poultry products, companion animal products, and aquaculture products. This segment offers its products to veterinarians, distributors, and animal producers. The Consumer Health Care segment manufactures and sells over-the-counter, foot care, and sun care products. This segment sells its products through wholesale and retail drug, food chain, and mass merchandiser outlets. The company has a collaboration agreement with Alder Biopharmaceuticals Inc. to identify therapeutic monoclonal antibody lead candidates for central nervous system disorders. Schering-Plough Corporation was founded in 1928 and is headquartered in Kenilworth, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Fred Hassan , 63
Chairman, Chief Exec. Officer, Pres and Chairman of Exec. Committee |
N/A
| N/A | Mr. Robert J. Bertolini , 47
Chief Financial Officer and Exec. VP |
N/A
| N/A | Ms. Carrie S. Cox , 51
Exec. VP and Pres of Global Pharmaceutical Bus. |
$
2.24M |
$
11.54M | Dr. Thomas P. Koestler Ph.D., 58
Exec. VP and Pres of Schering-Plough Research Institute |
N/A
| N/A | Mr. Thomas J. Sabatino Jr., 50
Exec. VP and Gen. Counsel |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.45% Nasdaq 
0.20%
Profile
